缺氧肿瘤来源的外泌体miR-31-5p通过负调节SATB2逆转EMT和激活MEK/ERK信号促进肺腺癌转移

核心信息

  • 论文英文标题: Hypoxic tumor-derived exosomal miR-31-5p promotes lung adenocarcinoma metastasis by negatively regulating SATB2-reversed EMT and activating MEK/ERK signaling
  • 期刊: J Exp Clin Canc Res
  • 发表年份: 2021
  • DOI: 10.1186/s13046-021-01979-7
  • PMID/PMCID: 34074322; PMC8167983

研究概览

Exosomal miRNA was co-cultured with LUAD cells to assess its biological effects on cell migration and metastasis both in vitro and in vivo. Our findings demonstrate that exosomal miR-31-5p exerts a crucial role in LUAD progression, and could serve as a diagnostic biomarker for LUAD.

核心发现

We found that HExo could significantly enhance the migration and invasion of normoxic LUAD cells.

MiRNA sequencing results suggested that miR-31-5p was largely internalized within HExo and could be taken up by normoxic LUAD cells.

Exosomal miR-31-5p was found to directly target Special AT-Rich Sequence-Binding Protein 2 (SATB2)-revered epithelial mesenchymal transition and significantly increase activation of MEK/ERK signaling, thereby contributing to tumor progression both in vitro and in vivo.

Furthermore, higher levels of circulating exosomal miR-31-5p were detected in LUAD patients, especially in patients with metastatic disease.

研究设计

Samples of miRNA isolated from hypoxic LUAD cell-derived exosomes (HExo) and normoxic LUAD cell-derived exosomes (NExo) were sequenced to identify miRNAs that might mediate tumor progression.

Exosomal miRNA was co-cultured with LUAD cells to assess its biological effects on cell migration and metastasis both in vitro and in vivo.

The cellular target of exosomal miRNA was confirmed by dual-luciferase assays.

Echo Biotech 角色

外泌体miRNA测序分析

关联平台: Exoomics®, Research Reagents & Tools

关联服务与能力: EV Isolation & Purification, EV miRNA Profiling / Sequencing, Research Reagent / Product Supply

关联产品或试剂: Exosupur® EV Isolation/Purification Kit

参考文献

原始论文: Hypoxic tumor-derived exosomal miR-31-5p promotes lung adenocarcinoma metastasis by negatively regulating SATB2-reversed EMT and activating MEK/ERK signaling J Exp Clin Canc Res. 2021. DOI: 10.1186/s13046-021-01979-7. PMID/PMCID: 34074322; PMC8167983.